NCT07935174
^68Ga-grazytracer PET for In Vivo Visualization of Immune Cell Effector Functions
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Incidence of Adverse Events Related to ⁶⁸Ga-grazytracer PET/CT Imaging
Timeframe: From tracer administration through completion of PET/CT imaging (approximately 2 hours).
Change in Maximum Standardized Uptake Value (SUVmax) on ⁶⁸Ga-grazytracer PET
Timeframe: Baseline and during the predefined treatment period (up to 6 months).
Change in Target-to-Background Ratio (TBR) on ⁶⁸Ga-grazytracer PET
Timeframe: Baseline and during the predefined treatment period (up to 6 months).
Secondary (1)
Area Under the ROC Curve (AUC) of ⁶⁸Ga-grazytracer PET SUVmax for Predicting Tumor Treatment Response
Arms and interventions
^68Ga-grazytracer PET ImagingExperimental
All enrolled participants will undergo \^68Ga-grazytracer PET/CT imaging according to the study protocol for noninvasive assessment of immune cell effector function. Participants include patients with cancer and autoimmune diseases. PET/CT imaging will be performed before treatment initiation and during the predefined treatment period according to the study protocol. Imaging findings will be correlated with clinical characteristics, treatment response, and disease activity.
Diagnostic tests: ^68Ga-grazytracer PET/CT
Sites
1 site in 1 country
- Peking University Third HospitalBeijing, Beijing Municipality, China